Ivermectin + Mebendazole: Groundbreaking Study Reports 84.4% Clinical Benefit Rate in Cancer Patients
A newly released observational analysis found that 84.4% of cancer patients treated off-label with a compounded combination of Ivermectin and Mebendazole experienced a clinical benefit.
16 Sep 11:50 · Breitbart